Transform 1 Study News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Transform 1 study . Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Transform 1 Study Today - Breaking & Trending Today

Adding Navitoclax to Ruxolitinib Doubles Spleen Volume Reductions for Myelofibrosis

Up-front treatment with navitoclax plus ruxolitinib significantly reduced spleen volume by 35% or more at week 24 vs ruxolitinib plus placebo in patients with myelofibrosis; however, a significant difference was not observed in total symptom score v. 4.0 between the arms, according to data from the phase 3 TRANSFORM-1 study. ....

United States , Naveen Pemmaraju , Department Of Leukemia , University Of Texas Md Anderson Cancer Center , Cancer Center , Navitoclax Plus Ruxolotinib , Ash Annual Meeting , Transform 1 Study , Md Anderson ,